MS

While Novartis combats generic onslaught in the courts, FDA approves first Gilenya copycats
Endpoints
Fri, 12/6/19 - 09:54 am
Novartis
FDA
Gilenya
MS
multiple sclerosis
Mylan
Dr Reddy's
Torrent Pharmaceuticals
Aurobindo
generics
Treating multiple sclerosis with the help of the gut microbiome
Fierce Biotech
Mon, 12/2/19 - 09:58 am
Brigham and Women's
microbiome
microRNA
multiple sclerosis
MS
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Motley Fool
Wed, 11/27/19 - 10:43 am
Biogen
MS
multiple sclerois
Alzheimer's disease
Tecfidera
aducanumab
Patient charity to pay $4M to settle kickback allegations
Beckers Hospital Review
Fri, 11/22/19 - 10:12 am
kickbacks
Medicare
Medicare fraud
MS
multiple sclerosis
Teva Pharmaceutical
Biogen
Novartis
Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Fierce Pharma
Tue, 11/19/19 - 02:41 pm
MS
multiple sclerosis
physicians
Novartis
Mayzent
Merck KGaA
Mavenclad
Biogen
Vumerity
Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says
Multiple Sclerosis News Today
Thu, 11/14/19 - 07:35 pm
Biogen
MS
multiple sclerosis
Vumerity
drug pricing
Tecfidera
Biogen, Alkermes win FDA approval of Tecfidera successor — but can they actually sell it?
Endpoints
Wed, 10/30/19 - 10:13 am
Biogen
Alkermes
FDA
multiple sclerosis
MS
Vumerity
Why People With MS Need Permission from Insurers To Take Life-Saving Drugs. It’s Not The Reason You Think.
Forbes
Mon, 10/28/19 - 10:39 am
MS
multiple sclerosis
patients
insurers
payers
drug pricing
A new company enters the Tecfidera fight, offering to kill two birds
Endpoints
Tue, 10/22/19 - 10:29 am
Biogen
Tecfidera
MS
flushing
Vitalis Pharmaceuticals
Sanofi breaks into digital therapeutics with mental health app for MS patients
Fierce Pharma
Tue, 09/17/19 - 09:57 am
Sanofi
digital therapeutics
Happyify Health
MS
multiple sclerosis
Biogen, wrestling MS rivals, touts 10 year-plus Tecfidera data
Fierce Pharma
Wed, 09/11/19 - 10:26 am
Biogen
Tecfidera
MS
multiple sclerosis
Does competition equal lower prices? MS drugs defied cost logic as challengers swarmed in
Fierce Pharma
Thu, 08/29/19 - 08:18 pm
multiple sclerosis
MS
drug pricing
Biogen
Roche
Sanofi
Novartis
Teva Pharmaceutical
Bayer
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
Biopharma Dive
Tue, 08/27/19 - 10:55 pm
drug pricing
MS
multiple sclerosis
Medicare
Tackling the remaining challenges of multiple sclerosis
Pharmaforum
Sat, 08/10/19 - 01:52 pm
Merck KGaA
MS
multiple sclerosis
evobrutinib
Lift off! Celgene MS effort launches hot air balloon to highlight brain health
Fierce Pharma
Mon, 08/5/19 - 11:14 am
Celgene
multiple sclerosis
MS
ozanimod
drug marketing
The patent play: Biogen gets a PhIII boost for its bit-better take on the blockbuster MS franchise drug Tecfidera
Endpoints
Tue, 07/30/19 - 11:29 am
Biogen
Alkermes
MS
multiple sclerosis
Vumerity
clinical trials
Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?
Endpoints
Thu, 05/30/19 - 09:42 am
Biogen
MS
multiple sclerosis
Tecfidera
ALKS 8700
Vumerity
Alkermes
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
Tue, 04/2/19 - 04:20 pm
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Celgene refiles ozanimod with FDA 1 year after regulatory snafu
Fierce Biotech
Wed, 03/27/19 - 10:20 am
Celgene
ozanimod
MS
multiple sclerosis
How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
Investors Business Daily
Wed, 03/13/19 - 10:13 am
Celgene
Novartis
ozanimod
MS
multiple sclerosis
patents
Bristol-Myers Squibb
M&A

Pages